Actively Recruiting
Evaluating the Safety and Effectiveness of a Paclitaxel-Coated Sinus Balloon with Endoscopic Sinus Surgery for Adults with Chronic Rhinosinusitis
Led by Airiver Medical, Inc. · Updated on 2026-10-29
300
Participants Needed
16
Research Sites
152 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a prospective, multicenter, randomized, controlled, and double-blind clinical trial involving 300 adults with chronic rhinosinusitis CRS, both with and without nasal polyps. The study aims to evaluate the safety and effectiveness of a paclitaxel-coated sinus balloon as an addition to standard endoscopic sinus surgery ESS for treating CRS. Participants must be suitable candidates for ESS based on specific diagnostic criteria and disease characteristics. Participants will be randomly assigned in equal numbers to either receive standard ESS alone or ESS followed by dilation of the treated sinuses using the investigational Airiver ESSpand drug-coated balloon DCB. All subjects will undergo traditional ESS of their diseased sinuses before randomization. This procedure will be conducted across up to 40 sites in the United States. During the trial, participants will undergo follow-up assessments including safety evaluations at 30 days after the initial procedure and efficacy assessments at 6 months post-procedure. Additional outcome measures include clinical responder rates and grading of sinus adhesion or scarring at 6 and 12 months. Participants are expected to comply with all follow-up visits and assessments throughout the study duration, which extends to the study completion date in 2031.
CONDITIONS
Brief Title
Paclitaxel-Coated Balloon Treatment of Chronic Rhinosinusitis
Research Team
S
Sr Clinical Operation Director
C
Chief Operation Officer
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here